Acacia Pharma Group plc Acacia Pharma Issues Ordinary Shares To Its Employee Benefit Trust
21 12월 2021 - 3:00PM
UK Regulatory
TIDMACPH
THIS ANNOUNCEMENT CONTAINS REGULATED INFORMATION.
Publication in application of Article 15 of the Law of 2 May 2007
(the Transparency Law)
-----------------------------------------------------------------
Acacia Pharma Group plc
As previously announced(1) , Acacia Pharma Group plc issued
ordinary shares to its Employee Benefit Trust within the authorised
capital. The gross amount of this capital increase amounted to GBP
22,909.44 via an issue of 1,145,472 new shares at an issue price of
GBP 0.02 per share. The shares were issued to satisfy the vesting
of share awards granted under the Company's Performance Share
Plan.
Total amount of share capital on 21
December 2021 GBP 2,017,188.46
------------------------------------- ------------------
Total amount of share premium on 21
December 2021 GBP 142,087,474.57
------------------------------------- ------------------
Total number of shares with voting
rights on 21 December 2021 100,859,423
------------------------------------- ------------------
Total number of voting rights on 21
December 2021 (denominator) 100,859,423
------------------------------------- ------------------
Total number of outstanding warrants 201,330
------------------------------------- ------------------
Total number of outstanding employee
share options and RSUs(2) 6,208,505
------------------------------------- ------------------
1. Press release of 16 December 2021 -- Issue of Shares to Employee Benefit
Trust
2. Of the 6,208,505 options and RSUs currently outstanding, 1,015,583 will
be satisfied through the transfer of shares already issued and admitted
to trading and held within the Acacia Pharma Group plc Employee Benefit
Trust
Contacts
Acacia Pharma Group plc International Media
Mike Bolinder, CEO Frazer Hall, Mark Swallow, David
Gary Gemignani, CFO Dible
+44 1223 919760 / +1 317 505 1280 MEDiSTRAVA Consulting
mailto:IR@acaciapharma.com IR@acaciapharma.com +44 20 7638 9571
mailto:acaciapharma@medistrava.com
acaciapharma@medistrava.com
----------------------------------------------- ------------------------------------
US Investors Media in Belgium and the Netherlands
LifeSci Advisors Chris Van Raemdonck
Irina Koffler +32 499 58 55 31
+1 917-734-7387 mailto:chrisvanraemdonck@telenet.be
mailto:ikoffler@lifesciadvisors.com chrisvanraemdonck@telenet.be
ikoffler@lifesciadvisors.com
----------------------------------------------- ------------------------------------
About Acacia Pharma
Acacia Pharma is a hospital pharmaceutical company focused on
the development and commercialization of new products aimed at
improving the care of patients undergoing significant treatments
such as surgery, other invasive procedures, or cancer chemotherapy.
The Company has identified important and commercially attractive
unmet needs in these areas that its product portfolio aims to
address.
Barhemsys(R) (amisulpride) injection is a selective dopamine (D2
and D3) receptor antagonist approved and available in the US for
the treatment and prevention of postoperative nausea & vomiting
(PONV) in adult patients.
Please see full prescribing information, including Important
Safety Information, at
https://www.globenewswire.com/Tracker?data=68BDDhs2QH9xu9mDQHBVO93Qv7wPBwdQJkVEtHY9WQ_OzhUXfUGgMwsF9C-9W6WO8ISpRzCjsdecLPlmE24Sf-57ygnB5nwRLSnIzdK5rciSOfhYLSMMMrc3qWD9WpRxr0iPjhHGG-8JyJBktvPN0V3r62ekFYx4qZz-c_4ksTZYDLfj5RskzNJ7RSZUJNjRWXEDP6giUYhHse4-YhXHxUjmDlc1--9jgKiD2n_vnPs=
www.BARHEMSYS.com.
Byfavo(R) (remimazolam) for injection, is an IV benzodiazepine
sedative approved and available in the US for the induction and
maintenance of procedural sedation in adults undergoing procedures
lasting 30 minutes or less. Byfavo is in-licensed from Paion UK
Limited for the US market.
Please see full prescribing information, including Important
Safety Information and Boxed Warning, at
https://www.globenewswire.com/Tracker?data=68BDDhs2QH9xu9mDQHBVOzsiWH4oPakS6-ZuJoJBMiFvLR-CpxNuXh15zXdAX4-SPCZaFw_NEl3iLtHI9z7YJjGjmuD4R1i47ZQ_CayPdNvFbrQ5RvvVN1n41eLU-6KxC2gowux9xJhNx5Ra83WGXb6bOQtN3PHXnvLkvRa5_EwTeTu3MO0C7MYSKiIrLhF9htDoCEAAN9WA75R_MGzdmoHyeFLhhHwZBi9hrSh2E9o=
www.BYFAVO.com.
APD403 (intravenous and oral amisulpride), a selective dopamine
antagonist for chemotherapy induced nausea & vomiting (CINV)
has successfully completed one proof-of-concept and one Phase 2
dose-ranging study in patients receiving highly emetogenic
chemotherapy.
Acacia Pharma has its US headquarters in Indianapolis, IN and
its R&D operations are centred in Cambridge, UK. The Company is
listed on the Euronext Brussels exchange under the ISIN code
GB00BYWF9Y76 and ticker symbol ACPH.
This release is intended for investors and media only.
https://www.globenewswire.com/Tracker?data=68BDDhs2QH9xu9mDQHBVOzVN5m-MPs8LyrL-kTS6HWN8xLFSAuxyo1q0ZoeKNKrP6tdgknvsWlkwHu-cv7YDwG43Sd6jGlzXynBEWod_2Uk=
www.acaciapharma.com
(END) Dow Jones Newswires
December 21, 2021 01:00 ET (06:00 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Acacia Pharma (LSE:0PNT)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Acacia Pharma (LSE:0PNT)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024